A new study reaffirms the benefits of TRT, at least among opioid users. The article says:
There may be mortality, musculoskeletal and cardiovascular benefits from testosterone therapy among men with low testosterone due to opioid use, according to findings published in JAMA Network Open.
Jasuja and colleagues assessed the risks for all-cause death, major adverse CV events, anemia and fractures at the femur, hip and vertebrae across 6 years in a cohort of 21,272 men using data from the Veteran’s Health Administration. Total testosterone levels less than 300 ng/dL or free testosterone levels less than 70 pg/mL were used as the criteria for low testosterone, which was present in all participants. The researchers also identified prescriptions for testosterone therapy of at least 120 days for 14,121 men (mean age, 52.8 years) and identified no prescriptions for testosterone therapy for 7,151 men(mean age 54.8 years).
There was a 49% reduction in all-cause mortality risk among testosterone users vs. nonusers (HR = 0.51; 95% CI, 0.42-0.61). Testosterone users also had a 42% reduction in major adverse CV event risk (HR = 0.58; 95% CI, 0.51-0.67) and a 32% reduction in fracture risk at the femur or hip (HR = 0.68; 95% CI, 0.48-0.96). The researchers also observed an association between testosterone therapy and anemia resolution, with the likelihood of resolution 16% greater for testosterone therapy users vs. nonusers (HR = 1.16; 95% CI, 1.02-1.31). Sensitivity analyses that included considerations for cancer, glucocorticoid medications and propensity score matching did not significa
There may be mortality, musculoskeletal and cardiovascular benefits from testosterone therapy among men with low testosterone due to opioid use, according to findings published in JAMA Network Open.
Jasuja and colleagues assessed the risks for all-cause death, major adverse CV events, anemia and fractures at the femur, hip and vertebrae across 6 years in a cohort of 21,272 men using data from the Veteran’s Health Administration. Total testosterone levels less than 300 ng/dL or free testosterone levels less than 70 pg/mL were used as the criteria for low testosterone, which was present in all participants. The researchers also identified prescriptions for testosterone therapy of at least 120 days for 14,121 men (mean age, 52.8 years) and identified no prescriptions for testosterone therapy for 7,151 men(mean age 54.8 years).
There was a 49% reduction in all-cause mortality risk among testosterone users vs. nonusers (HR = 0.51; 95% CI, 0.42-0.61). Testosterone users also had a 42% reduction in major adverse CV event risk (HR = 0.58; 95% CI, 0.51-0.67) and a 32% reduction in fracture risk at the femur or hip (HR = 0.68; 95% CI, 0.48-0.96). The researchers also observed an association between testosterone therapy and anemia resolution, with the likelihood of resolution 16% greater for testosterone therapy users vs. nonusers (HR = 1.16; 95% CI, 1.02-1.31). Sensitivity analyses that included considerations for cancer, glucocorticoid medications and propensity score matching did not significa
